Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 4/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480235 | 0.86 | PRMT1 (0.36) | EBPPRMT1OPRM1SIGMAR1AOC2 | |
| SCHEMBL12026643 | 0.80 | CYP2D6 (0.39) | PRMT1OPRK1OPRM1OPRL1AOC2 | |
| SCHEMBL22520604 | 0.76 | HRH3 (0.36) | EBPOPRK1OPRM1OPRL1SIGMAR1 | |
| SCHEMBL23329842 | 0.75 | HSD11B1 (0.43) | PRMT1AOC2 | |
| SCHEMBL22520769 | 0.75 | CHRM5 (0.43) | — | |
| SCHEMBL25480272 | 0.74 | HRH3 (0.44) | — | |
| SCHEMBL26958231 | 0.73 | DRD2 (0.37) | OPRK1OPRM1OPRL1DRD2OPRD1 | |
| SCHEMBL24233214 | 0.73 | HRH3 (0.35) | EBPOPRK1OPRM1OPRL1SIGMAR1 | |
| SCHEMBL14453909 | 0.73 | CHRM5 (0.41) | OPRM1OPRD1 | |
| SCHEMBL15907027 | 0.72 | PRMT1 (0.37) | PRMT1OPRK1OPRM1OPRL1AOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | EBP 1773/4885PRMT1 487/4885OPRK1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.